Publications by authors named "Manuel Javaloyas"

Article Synopsis
  • The study aimed to evaluate how HIV infection and combined antiretroviral therapy (c-ART) impact proatherogenic biomarkers and lipids, and their links to early signs of atherosclerosis in treatment-naive patients.
  • A comparative analysis was conducted with two groups of HIV-infected patients (one starting c-ART and the other not) alongside healthy controls, with various biomarkers measured at different time points using lab tests and carotid ultrasounds.
  • Results indicated that HIV-infected patients initially had poorer lipid profiles and higher inflammatory markers; however, those starting c-ART showed improvements in certain lipid levels and reductions in inflammatory markers over time, while signs of atherosclerosis increased in both groups of HIV patients.
View Article and Find Full Text PDF

Background: We assessed the strategy of substituting nevirapine, efavirenz, or abacavir for a protease inhibitor in patients infected with human immunodeficiency virus type 1 (HIV-1) in whom virologic suppression had been achieved.

Methods: We randomly assigned 460 adults who were taking two nucleoside reverse-transcriptase inhibitors and at least one protease inhibitor and whose plasma HIV-1 RNA levels had been less than 200 copies per milliliter for at least the previous six months to switch from the protease inhibitor to nevirapine (155 patients), efavirenz (156), or abacavir (149). The primary end point was death, progression to the acquired immunodeficiency syndrome, or an increase in HIV-1 RNA levels to 200 copies or more per milliliter.

View Article and Find Full Text PDF

Background And Objective: There are few studies analyzing the epidemiological characteristics of Escherichia coli bacteremia including the susceptibility to antibiotics and outcome.

Patients And Method: E. coli bacteremia episodes were recorded from January 1989 to December 1998.

View Article and Find Full Text PDF